Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;105(5):e261-e263.
doi: 10.3324/haematol.2019.235937. Epub 2020 Feb 27.

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial

Rakesh Popat  1 , Dana Warcel  2 , Jenny O'Nions  2 , Anna Cowley  2 , Sasha Smith  2 , William R Tucker  3 , Kwee Yong  2 , Simona Degli Esposti  3
Affiliations

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial

Rakesh Popat et al. Haematologica. 2020 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graphical representation of Case 4 showing decline in kappa light chains with Belantamb Mafodotin (belamaf) (doses represented by arrows). Treatments were planned to be given at 21 day intervals.
See this image and copyright information in PMC

References

    1. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. - PubMed
    1. Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. - PMC - PubMed
    1. Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653. - PMC - PubMed
    1. Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37. - PMC - PubMed
    1. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604. - PMC - PubMed